A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

  • STATUS
    Recruiting
  • End date
    Jun 26, 2022
  • participants needed
    60
  • sponsor
    Alnylam Pharmaceuticals
Updated on 26 November 2020
Investigator
Alnylam Clinical Trials Hotline
Primary Contact
Clinical Trial Site (3.1 mi away) Contact
+23 other location
polyneuropathy

Summary

To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.

Details
Treatment Patisiran
Clinical Study IdentifierNCT04201418
SponsorAlnylam Pharmaceuticals
Last Modified on26 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Hereditary Transthyretin-mediated (ATTRv) Amyloidosis or Peripheral Neuropathy or Hereditary Transthyretin-mediated (hATTR) Amyloidosis or Polyneuropa...?
Do you have any of these conditions: Peripheral Neuropathy or Polyneuropathy or Hereditary Transthyretin-mediated (ATTRv) Amyloidosis or Hereditary Transthyretin-mediated (hATTR) Amyloido...?
Do you have any of these conditions: Hereditary Transthyretin-mediated (ATTRv) Amyloidosis or Polyneuropathy or Peripheral Neuropathy or Hereditary Transthyretin-mediated (hATTR) Amyloido...?
Diagnosed with ATTRv amyloidosis with polyneuropathy, with a documented V122I or T60A mutation
PND score of I-IIIB at baseline
Exposure to commercial patisiran in one of the 3 cohorts
Prospective Cohort: Naive to patisiran treatment at the time of enrollment with intention to initiate treatment with patisiran
Mixed cohort: Currently on commercial patisiran therapy for less than 12 months at study enrollment
Retrospective cohort: Exposed to commercial patisiran treatment for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment

Exclusion Criteria

New York Heart Association (NYHA) heart failure classification 3
Karnofsky Performance Status (KPS) <60%
Unstable congestive heart failure (CHF)
Known primary amyloidosis (AL) or leptomeningeal amyloidosis
Prior major organ transplant
Previously received patisiran
Previous treatment with a TTR silencing therapy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet